18.04.2018 • NewsCepsaElaine Burridge

Cepsa Upgrades San Roque LAB Plant

Cepsa Upgrades San Roque LAB Plant (c) Max Lindenthaler/Shutterstock
Cepsa Upgrades San Roque LAB Plant (c) Max Lindenthaler/Shutterstock

Spanish energy and chemicals company Cepsa has announced plans to spend €100 million to upgrade and expand capacity of linear alkylbenzene (LAB) at its Puente Mayorga plant in San Roque, Cadiz.

The company will install the latest version of its Detal Plus technology, which it co-licenses with UOP. Cepsa said the plant will be the first in the world that will change the process from hydrofluoric hydric acid to Detal transalkylation technology.

Work will start in May and take approximately two years to complete. Capacity will rise by 50,000 t/y to a total of 250,000 t/y.

“The Puente Mayorga Chemical Plant is where our experience in the surfactant market began, which we have applied to our other installations around the world,” noted José Manuel Martínez, Cepsa’s chemical director. He added that the project “will allow us to revamp the plant and enhance its competitiveness in the market.”The increase in production from this plant will be primarily aimed at high growth African markets. Our estimations show LAB demand in these countries growing by 5% annually between now and 2035.”

Cepsa produces LAB in Spain, Canada and Brazil, with total combined production representing 15% of global supply. It said the project would help to strengthen its international leadership position in producing LAB, which will reach a global capacity of 650,000 t/y. According to Cepsa, four out of every five new LAB plants are currently built using Detal technology.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read